Literature DB >> 10027525

Adenocarcinoma with signet ring cells of the axilla showing apocrine features: a case report.

Y Kuno1, T Numata, T Kanzaki.   

Abstract

A 74-year-old Japanese man developed a reddish, indurated plaque composed of multiple nodules on his right axilla. Histopathologic examination showed a solid tumor that extended from the upper dermis into the subcutis, with both inter- and intracellular lumen formation, cellular arrangement in single files, a fibrotic reaction around the tumor cells, and the presence of mucinous material in the cytoplasm. There was both nuclear and cytoplasmic pleomorphism. Both lysozyme and GCDFP-15 were identified in the tumor cells. Electron microscopic examination showed periluminal condensation of the cytoplasm. Because thorough clinical and laboratory examinations were unremarkable, we regarded this to be a case of primary adenocarcinoma with signet ring cells of the axilla. The neoplasm might have differentiated toward the apocrine sweat glands or the mammary glands. Radiation therapy was effective to some degree. This seems to be the first reported case in which adenocarcinoma with signet ring cells of the skin affected a site other than the eyelids.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10027525     DOI: 10.1097/00000372-199902000-00009

Source DB:  PubMed          Journal:  Am J Dermatopathol        ISSN: 0193-1091            Impact factor:   1.533


  3 in total

1.  [Suspected tumor of the upper eyelid].

Authors:  R Kempin; V Rosenthal; F Tost
Journal:  Ophthalmologe       Date:  2013-11       Impact factor: 1.059

2.  Primary cutaneous apocrine carcinoma of sweat glands: a rare case report.

Authors:  T Vasilakaki; E Skafida; E Moustou; X Grammatoglou; E Arkoumani; K Koulia; A Tsavari; E Delliou
Journal:  Case Rep Oncol       Date:  2011-12-17

3.  Primary Signet Ring Cell/Histiocytoid Carcinoma of the Eyelid: Somatic Mutations in CDH1 and Other Clinically Actionable Mutations Imply Early Use of Targeted Agents.

Authors:  Lei-Chi Wang; Tai-Chi Lin; Yi-Chen Yeh; Hsiang-Ling Ho; Chieh-Chih Tsai; Teh-Ying Chou
Journal:  Curr Oncol       Date:  2021-02-16       Impact factor: 3.677

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.